![](https://endpts.com/wp-content/uploads/2019/07/Harpreet-Singh-Immatics-credit-Allogeneic-Cell-Therapies-Summit.jpg)
Harpreet Singh, Immatics CEO
Immatics imagines broader CAR-T pipeline with another Bristol Myers pact and addition to 2019 TCR deal
Immatics is hitting the gas pedal on another Bristol Myers Squibb deal as the biotech-Big Pharma pair also level up their 2019 pact, originally inked …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.